Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma

• Type of Material: Article
• Authors: Alexander Villalobos, Emory University; William Wagstaff, Emory University; Mian Guo, Emory University; James Zhang, Emory University; Zachary Bercu, Emory University; Morgan J. Whitmore, Emory University; Mircea M. Cristescu, Emory University; Bill Majdalany, Emory University; Joel Wedd, Emory University; Mehmet Akce, Emory University; Joseph Magliocca, Emory University; Marty Sellers, Emory University; Nima Kokabi, Emory University
• Language: English
• Date: 2021-07-23
• Publisher: Hindawi
• Publication Version: Final Published Version
• Copyright Statement: © 2021 Alexander Villalobos et al.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1155/2021/9926704
• Title of Journal or Parent Work: Canadian Journal of Gastroenterology and Hepatology
• Volume: 2021
• Research Categories: Health Sciences, Pharmacology; Health Sciences, Oncology

Abstract

Purpose This study aims to identify clinical and imaging prognosticators associated with the successful bridging or downstaging to liver transplantation (LT) in patients undergoing Yttrium-90 radioembolization (Y90-RE) for hepatocellular carcinoma (HCC). Methods Retrospectively, patients with Y90-RE naïve HCC who were candidates or potential candidates for LT and underwent Y90-RE were included. Patients were then divided into favorable (maintained or achieved Milan criteria (MC) eligibility) or unfavorable (lost eligibility or unchanged MC ineligibility) cohorts based on changes to their MC eligibility after Y90-RE. Penalized logistic regression analysis was performed to identify the significant baseline prognosticators. Results Between 2013 and 2018, 135 patients underwent Y90-RE treatment. Among the 59 (42%) patients within MC, LT eligibility was maintained in 49 (83%) and lost in 10 (17%) patients. Within the 76 (56%) patients outside MC, eligibility was achieved in 32 (42%) and unchanged in 44 (58%). Among the 81 (60%) patients with a favorable response, 16 (20%) went on to receive LT. Analysis of the baseline characteristics revealed that lower Albumin-Bilirubin score, lower Child–Pugh class, lower Barcelona Clinic Liver Cancer stage, HCC diagnosis using dynamic contrast-enhanced imaging on CT or MRI, normal/higher albumin levels, decreased severity of tumor burden, left lobe HCC disease, and absence of HBV-associated cirrhosis, baseline abdominal pain, or fatigue were all associated with a higher likelihood of bridging or downstaging to LT eligibility (p's < 0.05). Conclusion Certain baseline clinical and tumor characteristics are associated with the successful bridging or downstaging of potential LT candidates with HCC undergoing Y90-RE.